Max Robotics — Global Service Robot Directory + US Certification

About

Kristin Kaiser is a translational cancer researcher whose work focuses on precision oncology in ovarian carcinoma, particularly through the lens of homologous recombination deficiency (HRD). Her landmark study, “Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort,” has garnered 40 citations and established her as a key voice in biomarker-driven therapy. In this work, Kaiser evaluated HRD across 514 ovarian tumor samples using next-generation sequencing, analyzing BRCA1/BRCA2 mutations alongside over 26,000 single-nucleotide polymorphisms to refine diagnostic criteria for targeted treatment strategies. Her contributions directly impact how clinicians identify patients likely to benefit from PARP inhibitors, bridging the gap between genomic discovery and real-world clinical application. Kaiser’s research exemplifies the integration of large-scale genomic data into routine oncology practice, offering a model for precision medicine that is both scalable and actionable. Her findings continue to shape guidelines for HRD testing, underscoring her role in advancing therapeutic decision-making for ovarian cancer patients.